Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 10/20 | 0.67 |
| ▸ | CA1 | P00915 | 10/20 | 0.67 |
| ▸ | CA2 | P00918 | 10/20 | 0.67 |
| ▸ | CA9 | Q16790 | 10/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | IDE | P14735 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31019320 | 0.91 | GBA1 (0.58) | CA12CA1CA2CA9PKM | |
| SCHEMBL31578430 | 0.85 | CA12 (0.74) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL12807414 | 0.84 | CA12 (0.75) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL6372736 | 0.84 | CA12 (0.79) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL9412855 | 0.83 | CA12 (0.75) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL14308477 | 0.81 | CA12 (0.72) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL9412854 | 0.80 | CA12 (0.73) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL18268938 | 0.78 | CA12 (0.60) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL31578520 | 0.78 | CA12 (0.64) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL12735647 | 0.78 | CA12 (0.69) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | THE JOHNS HOPKINS UNVERSITY | 2025-04-10 | — | — | US | disclosed |
| WO-2025058000-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING AND/OR DIAGNOSING CANCER | 東レ株式会社 | 2025-03-20 | — | — | WO | disclosed |
| US-20240410876-A1 | EXTRACELLULAR VESICLE DRUG ANALYSIS FOR REAL-TIME MONITORING OF TARGETED THERAPY | NAT UNIV SINGAPORE (SG) | 2024-12-12 | — | — | US | disclosed |
| US-20240117431-A1 | STEM-CELL BASED BIOMARKER DISCOVERY | UNIV CALIFORNIA (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2023033129-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | 東レ株式会社 | 2023-03-09 | — | — | WO | disclosed |
| WO-2022168055-A1 | EXTRACELLULAR VESICLE DRUG ANALYSIS FOR REAL-TIME MONITORING OF TARGETED THERAPY | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | OPRM1, OPRK1, OPRL1 | CA12 3323/4885CA1 4438/4885CA2 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.